- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07332650
Előrehaladó klinikai vizsgálat a Juläine™ biztonságának és teljesítményének értékelésére a gluteális bőrlaxitás javításában felnőtteknél.
Prospektív klinikai vizsgálat a Poly-L-laktát sav - Juläine™ gluteális bőr lazaságának javításában betöltött biztonságosságának és teljesítményének értékelésére felnőtteknél.
This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.
Participants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.
The primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.
This multicenter trial will be conducted in Brazil.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
This is an pivotal, open-label, two-arm, randomized, parallel-group, prospective clinical investigation conducted in Brazil to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) administered as subcutaneous injections for the treatment skin laxity in the buttock (gluteal) region in adults.
A total of 100 participants will be randomized to either an immediate-treatment group or a delayed-treatment group (delayed-start control). Participants in the immediate-treatment group will receive Juläine™ subcutaneous injections in 2 or 3 sessions at Day 0, Day 30, and Day 60. During this initial control period, outcomes in the immediate-treatment group will be compared with those in the delayed-treatment group, which will not receive treatment. After the control period, participants in the delayed-treatment group will receive the same Juläine™ regimen at Day 240, Day 270, and Day 300. Each participant will remain in the study for up to 16 months, excluding screening.
The primary efficacy endpoint is improvement in buttock skin elasticity 6 months after the last injection defined as an increase in global skin elasticity measured by a cutometer, with assessments at screening/baseline and at the primary post-treatment timepoint. The mean change in global skin elasticity measured by cutometer and Global Aesthetic Improvement Scale (GAIS) will also be evaluated, comparing groups during the control period.
Safety will be monitored through the collection of adverse events (AEs) through 240 days after randomization, with comparisons between groups during the control period. Adverse events will also be evaluated through extended follow-up, including up to 180 days in the overall study population and up to 480 days in the immediate-treatment group.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Adults aged 18 to 55 years;
- Body Mass Index (BMI) between 18.5 and 24.95 kg/m².
- Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.
- Women of childbearing potential must be willing to abide by the contraceptive requirements
- Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions.
Exclusion Criteria:
- Pregnancy or breastfeeding, or planned pregnancy/lack of adequate contraception (through 8 weeks post-study);
- Is planning to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.
- Active infection, inflammation or lesions at or near the treatment site.
- Acute infection at screening;
- History of autoimmune disease;
- Immune deficiencies;
- History of hypertrophic scarring or keloid formation;
- History of thrombosis in the lower limbs.
- Previous surgical procedures involving the buttocks
- Previous treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
- Previous aesthetic procedures in the treatment area, including radiofrequency, ultrasound, cryotherapy, neurotoxin, laser or light treatment, or chemical peel, within six months before randomization.
- Previous topical or home therapy for cellulite in the treatment area within three months before randomization.
- Hemorrhagic disease or ongoing use of antiplatelets/anticoagulant therapy.
- Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).
- Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.
- Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.
- Use of other agents that inhibit collagen production.
- Known allergy or hypersensitivity to any component of the investigational product.
- History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.
- Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).
- Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.
- Presence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
- Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected >10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change >10%, may be included.
- Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Azonnali kezelés csoport
|
Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres. |
|
Egyéb: Késleltetett kezelésű csoport (késleltetett kezdésű kontroll)
|
Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres. |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Proportion of participants who achieve an improvement in gluteal skin elasticity
Időkeret: Baseline and 240 days after randomization
|
Proportion of participants achieving a clinically significant reduction in gluteal skin laxity at Day 240 after randomization, whereby a clinically significant reduction ("response") is defined as a relative increase of at least 10% in the gross elasticity measured by cutometer at Day 240 compared to baseline. |
Baseline and 240 days after randomization
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Mean change in overall skin elasticity
Időkeret: Baseline and Day 240 after randomization.
|
Mean change in global medial skin elasticity measured by cutometer 180 days after treatment completion. |
Baseline and Day 240 after randomization.
|
|
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by investigator
Időkeret: Baseline and Day 240 after randomization.
|
Proportion of participants with at least a 1-point improvement in GAIS as rated by the investigator at Day 240 after randomization. The GAIS scale values are:
Where 1 represents the best outcome and 5 represents the worst. |
Baseline and Day 240 after randomization.
|
|
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by participant
Időkeret: Baseline and Day 240 after randomization.
|
Proportion of participants with at least a 1-point improvement in GAIS as rated by the participant at Day 240 after randomization The GAIS scale values are:
Where 1 represents the best outcome and 5 represents the worst. |
Baseline and Day 240 after randomization.
|
|
Proportion of adverse events (AEs)
Időkeret: Occurring up to 240 days after the start of treatment, in both groups.
|
Proportion of adverse events (AEs) occurring up to 240 days after randomization. |
Occurring up to 240 days after the start of treatment, in both groups.
|
|
Incidence and severity of Adverse events in the first 30 days
Időkeret: First 30 days after each Juläine™ administration, in all treated participants.
|
Incidence and severity of Adverse events in the first 30 days after each Juläine™ administration, in all treated participants. |
First 30 days after each Juläine™ administration, in all treated participants.
|
|
Incidence and severity of AEs up to 240 days.
Időkeret: Up to 240 days after start of treatment in all treated participants.
|
Incidence and severity of AEs up to 240 days after start of treatment in all treated participants. |
Up to 240 days after start of treatment in all treated participants.
|
|
Incidence and severity of AEs up to 480 days
Időkeret: Up to 480 days after start of treatment in the immediate-start group.
|
Incidence and severity of AEs up to 480 days after start of treatment in the immediate-start group. |
Up to 480 days after start of treatment in the immediate-start group.
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- NB 15-TF-BZ-100-08F
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .